Forty-eight patients with HR+ HER2- metastatic breast cancer enrolled in BRACELET-1 between June 2020 and June 2022. The median age was 55 (range 37-74).

Yet, many years later, the ability of frozen samples to preserve cancer biology is vividly demonstrated, enabling the discovery of new plasma membrane targets in trastuzumab-resistant HER2+ breast ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical ...

They report in Cell Reports Medicine that conducting an integrated proteogenomic profiling of cancer cells, which combines the analysis of DNA, RNA, protein and phosphoprotein data, revealed two novel ...

The neoCARHP study aimed to evaluate the efficacy and safety of a de-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer.

A total of 13.5% of tumors were HER2-positive. 1 Breast cancer was usually diagnosed at stage I or II, with less than 20% of patients having stage III or IV disease 1 : 34.6% stage I ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the DESTINY-Breast03 trial, as well as several other indications, including HR ...

According to the companies, ER+/HER2- breast cancer accounts for approximately 70% of all cases. 1 “Patients whose tumors harbor ESR1 mutations can face a poor prognosis, often experiencing rapid ...

Among HER2-overexpressing gastric cancer patients, compared to the PD-1-trastuzumab-CAPOX combination therapy, DV and PD-1 + chemotherapy as well as DV and PD-1 + trastuzumab both demonstrated ...

A new study shows that racial and ethnic disparities among Medicare beneficiaries who receive ERBB2 (formerly HER2)-targeted therapies for breast cancer have narrowed significantly from 2010 to ...

Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo's Enhertu has now shown efficacy in tumours that express lower levels of HER2 – potentially ...

UK recommendations for HER2 assessment in breast cancer: an update. E A Rakha and others. Journal of Clinical Pathology, 2023. Volume 76, Issue 4, Pages 217-227. Guidelines for cytogenetic ...